Foghorn Therapeutics Inc. <FHTX.OQ> expected to post a loss of 34 cents a share - Earnings Preview

ReutersMay 2, 2025 1:49 PM

View all comments（0）



Foghorn Therapeutics Inc. FHTX.OQ FHTX.O is expected to show a rise in quarterly revenue when it reports results on May 5 (estimated) for the period ending March 31 2025
The Cambridge Massachusetts-based company is expected to report a 15.2% increase in revenue to $5.816 million from $5.05 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Foghorn Therapeutics Inc. is for a loss of 34 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Foghorn Therapeutics Inc. is $10.00, above its last closing price of $4.16.

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER ENDING	STARMINESMARTESTIMATE®	LSEG IBES ESTIMATE	ACTUAL	BEAT, MET, MISSED	SURPRISE %
Dec. 31 2024	-0.27	-0.33	-0.30	Beat	8.3
Sep. 30 2024	-0.42	-0.44	-0.31	Beat	29.6
Jun. 30 2024	-0.63	-0.65	-0.45	Beat	31.3
Mar. 31 2024	-0.56	-0.63	-0.59	Beat	6.9
Dec. 31 2023	-0.94	-0.76	-0.57	Beat	25.3
Sep. 30 2023	-0.74	-0.75	-0.34	Beat	54.7
Jun. 30 2023	-0.74	-0.73	-0.70	Beat	4.8
Mar. 31 2023	-0.68	-0.72	-0.73	Missed	-0.7

This summary was machine generated May 2 at 13:49 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Today’s Market Recap: US Inflation Hits 3-Year Peak as Market Braces for Trump’s China Visit and Fed Leadership Shift

April inflation hit a three-year peak of 3.8%, pressuring the Nasdaq and tech stocks. Markets are further braced by Kevin Warsh’s Fed Chair confirmation, the maintenance of Trump’s 10% global tariffs, and a high-profile U.S. business delegation preparing for a strategic state visit to China.

BigBear.ai Stock Down 26% YTD – Should You Invest in BBAI Stock in 2026? Can the Ask Sage Deal Lead to a Rebound?

TradingKey - BigBear.ai (BBAI) provided a modest first-quarter update on May 5, and BBAI shares have declined about 26% year to date. The company finalized the acquisition of Ask Sage in January, marking its shift away from a services-heavy government contractor to a platform-centric AI company. The

Renesas Electronics Rises Over 7%, SoftBank Rises Over 4%, Can Japanese Chip Stocks Replicate South Korean Stocks’ Soaring Rally?

TradingKey - On May 12, Japanese chip stocks strengthened significantly, with Renesas Electronics rising 7.14%, Sumitomo Metal Mining gaining 5.61%, and SoftBank Group advancing 4.25%. The Nikkei 225 Index climbed more than 700 points at one point during the day.

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

TradingKey - Cerebras Systems (CBRS) IPO prices May 13–14 at $125–$135/share. $26–$27B valuation, 20x oversubscribed, $510M revenue, 47% net margin, OpenAI 750MW deal. Everything you need to know.

AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

TradingKey - On May 5 (ET), Advanced Micro Devices (AMD) released its first-quarter fiscal 2026 financial results after the market close. The company reported revenue of $10.253 billion, up 38% year-over-year, exceeding market expectations of $9.89 billion. Non-GAAP earnings per share (EPS) were $1.

Featured Tools